Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ACADIA Pharmaceuticals Inc. (ACAD), Pfizer Inc. (PFE): Sabby Management Rewarded for Its Healthcare Picks

Page 1 of 2

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) spiked nearly 18% during Tuesday’s intraday trading and hit a 52-week high of $46.48. The price action was due to speculations that there might be an acquisition deal looming just around the corner, since the biopharmaceutical company cancelled its presentation at the Roth Conference. This was the second time that the company cancelled attending an event, the first one being the Cowen Conference on 3rd March. One investor, who was pleased with the news is Sabby Capital‘s Hal Mintz. He initiated a position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) just last quarter by purchasing some 864,400 shares valued at $27.45 million, according to Sabby’s latest 13F filing.

Acadia Healthcare Company Inc (NASDAQ:ACHC)

In fact, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been able to spike the interest of prominent hedge fund managers during the fourth quarter. Among others, Ken Griffin’s Citadel Investment Group, increased its stake by 11% to around 896,600 shares valued at $28.47 million and Steven Cohen’s Point72 Asset Management, which also upped its stake by 11% to 1.02 million shares. Acadia is a biotechnology company focused on the development and commercialization of medicines to address unmet medical needs in neurological and related central nervous system disorders. The company is currently in Phase III developmental stage of its landmark drug Nuplazid, which could potentially become the first drug to treat Parkisnson’s disease in the U.S. That said, since at this time acquisition talks are merely a speculation, there could be a variety of other reasons why ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s management cancelled the conferences. These range from data to be presented still being in the preparation phase to even waiting for some sort of response from the FDA.

Even though ACADIA posted a net loss per share of $0.28 for the fourth quarter, it has sufficient cash locked up to fund the commercialization of Nuplazid itself, once the drug is approved. At the end of the quarter cash, cash equivalents and investment securities amounted to $322.5 million. If a deal is indeed on the cards, ACADIA is not going to sell itself cheaply.

Although founded recently in 2012, Sabby Capital’s principal and managing member, Hal Mintz has a considerable experience in investment finance. He  was co-general partner of the BAM Opportunity Fund L.P., which was launched in July 2002, and prior to that he was a proprietary equity derivative trader and limited partner for Orbit 2 Partners L.P, between 1996 and 2001. Mintz has a magna cum laude bachelor’s in business administration from the Olin School of Business at Washington University. Sabby Capital is health care focused hedge fund, with 87% of its holdings in that sector. It also had a particularly high turnover ratio of 60.08% during the fourth quarter. A total of 67 new positions were initiated, of which the top two in terms of value were Pfizer Inc. (NYSE:PFE) and  ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Market Value of its portfolio stood at $3.17 billion.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!